Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Publisert: 12.10.2021

Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Publisert: 07.09.2021

Navamedic ASA: Q2 and first half 2021 financial results

Publisert: 13.08.2021

Navamedic ASA: Invitation to 2021 Second quarter presentation

Publisert: 10.08.2021

Treating the side-effects of the pandemic

Publisert: 24.06.2021

Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market

Publisert: 17.06.2021